Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 118 participants.

Also called NCT03535935

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 118 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03535935
Other papers using this trial's data
  • Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024-07-25 DOI, PubMed 38810556

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03535935. Randomized; single masking; primary purpose treatment. Start 2018-07-01 (actual); primary completion 2022-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease
Acronym
READY
Condition
Diabetic Nephropathies
Condition
Diabetic Kidney Disease
Intervention (Drug)
Astragalus Powder
Intervention (Other)
Routine medical care (active comparator)
Lead sponsor
The University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct03535935
Content hash
426f1e255f9ab38999cff9fc7a4d4e133e91a228cf3fff4fca702d9022c01a13